Transparency is healthy for a company. I am reasonably convinced the drug works. Therefore, for me, timely enrollment is the single biggest driver of the approval mechanism, as well as the stock price. If we know enrollment is moving as promised, we now we're in good shape, the stock price rises, and the patients will have a drug that will save their lives. Win, win, win. Enrollment determines whether we're first with a cure or not.

When companies see their investors are interested in metrics that are available, if they are transparent, they will make the data available. There is nothing proprietary about the number of patients enrolled. If investors ask for it, two things happen. The first is management knows investors are concerned about it and, hopefully, they are responded to. More importantly, if investors are watching that number, management will work harder to improve it.

That's human behavior. If CYDY is first to market, all or most of the other indications will have funding. If we're not first, and we're behind some large drug companies, it ain't gonna be that way. Right now, it looks like we're in first place. Confirming that increases the determination of both the stockholders and the people on the front lines. Everyone wants to either be a winner or be part of a winning team. All are motivated to make the number when all are watching. It is what it is. Ask for the number.